



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification⁴ : C07C 143/68, 143/70 A61K 31/385, 31/39, 31/255 C07D 327/00, C07F 7/08	A1	(11) International Publication Number: WO 85/ 03075 (43) International Publication Date: 18 July 1985 (18.07.85)
(21) International Application Number: PCT/US85/00057 (22) International Filing Date: 14 January 1985 (14.01.85) (31) Priority Application Number: 570,786 (32) Priority Date: 16 January 1984 (16.01.84) (33) Priority Country: US (71)(72) Applicant and Inventor: CRONYN, Marshall. W. [US/US]; 3232 Northwest Luray Terrace, Portland, OR 97210 (US). (74) Agents: DEHLINGER, Peter, J. et al.; Ciotti & Mu- rashige, 800 Menlo Avenue, Suite 102, Menlo Park, CA 94025 (US).		(81) Designated States: AT (European patent), BE (Euro- pean patent), CH (European patent), DE (European patent), FR (European patent), GB (European pa- tent), JP, LU (European patent), NL (European pa- tent), SE (European patent). Published <i>With international search report.</i>
(54) Title: CANCER CHEMOTHERAPEUTIC CYCLIC AND ACYCLIC DISULFONIC ESTER COMPOUNDS, METHOD OF USE THEREFOR, AND INTERMEDIATES		
(57) Abstract Bifunctional cyclic disulfonic ester compounds effective in treating certain types of cancers. Initial nucleophilic reaction with the compound produces a negatively charged sulfonic acid end-group which remains attached to the com- pound until a second alkylation reaction can occur.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GA	Gabon	MR	Mauritania
AU	Australia	GB	United Kingdom	MW	Malawi
BB	Barbados	HU	Hungary	NL	Netherlands
BE	Belgium	IT	Italy	NO	Norway
BG	Bulgaria	JP	Japan	RO	Romania
BR	Brazil	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	LI	Liechtenstein	SN	Senegal
CH	Switzerland	LK	Sri Lanka	SU	Soviet Union
CM	Cameroon	LU	Luxembourg	TD	Chad
DE	Germany, Federal Republic of	MC	Monaco	TG	Togo
DK	Denmark	MG	Madagascar	US	United States of America
FI	Finland	ML	Mali		
FR	France				

-1-

CANCER CHEMOTHERAPEUTIC CYCLIC AND ACYCLIC
DISULFONIC ESTER COMPOUNDS, METHOD OF USE
THEREFOR, AND INTERMEDIATES.

1. Field of the Invention

The present invention relates to bifunctional
5 alkylating compounds; in particular, to cyclic
disulfonic ester alkylating compounds.

2. Background

Alkylating agents are a major class of cancer
chemotherapeutic compounds. Most clinically used
alkylating agents are bifunctional compounds having two
chemically reactive centers capable of reacting with and
either fragmenting or cross-linking biomolecules, such
as the opposite strands of duplex DNA, or DNA and
associated protein. Use of these agents to alkylate
15 biomolecules leads to a variety of defects in
intracellular metabolism, particularly defects in
nucleic acid replication and/or transcription, which
tend to be more lethal in rapidly growing cancer cells
than in normal, somatic cells.


20 One class of bifunctional alkylating agents
include linear, uncharged disulfonates, exemplified by
Busulfan (Myleran, Burroughs Wellcome), which is
commonly used in the treatment of leukemias. Guide to
Therapeutic Oncology, Bergevin, P. R., et al, eds,
25 Williams and Wilkins, Baltimore/London (1979), p 110. A
compound of this type acts through an initial
nucleophilic reaction with a target biomolecule, such as
a DNA base, alkylating the target and splitting off a
free, charged sulfonic acid group. The uncharged
30 sulfonic-ester alkylating group may then participate in
a second nucleophilic reaction, to crosslink the
original target molecule to a second target and split

-2-

off a second sulfonic acid group. That is, the bifunctional reaction scheme involves an uncharged intermediate alkylating group. The 1,4-butanediol sulfonate (Bulsulfan) is more effective therapeutically than shorter or longer alkyl-chain linear sulfonates.

3. Summary of the Invention

The present invention includes cyclic disulfonic esters having the general structural formula:




10 where $m=0$ or 1 , $n=1-5$, and $R=\text{H}$, CH_3 , CH_3CH_2 or Cl . The compounds of the invention are useful as bifunctional agents for fragmenting biomolecules, such as DNA, or cross-linking a variety of nucleophilic-containing biomolecules, such as nucleic acids and
15 associated proteins. The cyclic disulfonic ester in which $m=0$, $n=2$ and $R=\text{H}$ is effective in the treatment of a variety of animal cancers, including mammalian lymphocytic leukemia, lymphoid leukemia, melanocarcinoma, human breast xenograft and ovarian
20 carcinoma. Cyclic disulfonic esters in which $m=0$, $n=3$ or 4 and $R=\text{H}$ have also been shown to have anti-leukemic activity.

Unlike linear disulfonic esters (where the butanediol compound is most therapeutically effective)
25 among cyclic compounds of the present invention, the disulfonic esters of ethanediol ($n=2$) and pentanediol ($n=5$) appear to be the most active in treating leukemic animals. The cyclic esters of the present invention are also shown herein to be effective in treating a variety
30 of cancer types other than leukemias, particularly


-3-

melanocarcinomas, breast xenografts and ovarian carcinomas.

Also unlike uncharged linear alkane disulfonates such as Busulfan, initial nucleophilic
 5 attack on a cyclic diester compound of the invention, in opening the diester ring, results in an intermediate linear sulfonate having a charged sulfonic acid end-group. In this regard, the invention more generally includes a bifunctional cross-linking agent capable of
 10 reacting with a first nucleophile- N_1 to produce a nucleophile-reactive intermediate of the form



where n, m and R are as identified above. The agent may be a cyclic compound of the type described above or a
 15 linear compound of the form



The invention further includes methods for synthesizing cyclic disulfonic ester compounds of the type described. In one method, useful particularly for
 20 synthesizing the n=1 cyclic disulfonic ester of the above structure, an alkanedisulfonyl chloride is allowed to react with a silver salt to form the corresponding silver disulfonate, which is then allowed to react with a dihaloalkane, such as dibromoethane or diiodomethane.
 25 In a second method, useful in the preparation of n=2-5 compounds, an alkanedisulfonyl chloride is allowed to react directly with an alkanediol in the presence of an aliphatic or aromatic tertiary amine, such as triethylamine or collidine. The tertiary amine is added
 30 dropwise to the other reactants at a low temperature to avoid alkylation of the amine by the product ester.

-4-

Another aspect of the invention includes a method of treating mammalian cancers, particularly lymphocytic and lymphoid leukemia, melanocarcinoma, human breast xenograft and ovarian carcinoma, which
5 comprises treating the cancerous mammal with a therapeutically effective amount of the cyclic disulfonic acid compound.

A general object of the invention is to provide a new class of cross-linking compounds which are
10 therapeutically effective in the treatment of several types of cancer.

Another object of the invention is to provide a disulfonic ester bifunctional cross-linking agent capable of reacting with a first nucleophile to produce
15 a nucleophile-reactive intermediate having a charged sulfonic acid end group.

Yet another object of the invention is to provide a class of cyclic bifunctional alkylating compounds which are readily synthesized in yields
20 suitable for drug testing and manufacture.

These and other objects and features of the invention will become more fully apparent from the following detailed description of the invention and accompanying examples.

25 Detailed Description of the Invention


The cyclic disulfonic esters of the present invention are synthesized according to novel methods described below in Section I. Section II describes the reaction of cyclic disulfonic esters with DNA, to
30 produce DNA strand breaks and DNA cross-linking to associated proteins. The section also considers a linear disulfonic ester having charged sulfonic acid end groups. This compound may react with duplex DNA in a

-5-

manner similar to that of the cyclic compound. A method of synthesis of the linear charged cross-linking agent is also described. Various drug treatment regimens in which selected cyclic disulfonic ester compounds are employed in the treatment of five different types of mammalian cancers are outlined in Section III.


I. Synthesis of Disulfonic Ester Cross-linking Agents

The present invention includes cyclic disulfonic esters having the general structural formula:



where $m=0$ or 1 , $n=1-5$, and $\text{R}=\text{H}$, CH_3 , CH_3CH_2 , or Cl .

The first synthetic method to be considered is particularly suitable for the synthesis of compounds of this type in which $n=1$. The method generally includes allowing an alkane disulfonyl chloride of the form:




where m and R are as indicated above, to react with a silver salt, preferably silver carbonate, under conditions which produce the corresponding silver disulfonate. Experimentally, the reaction is preferably carried out in the dark under completely anhydrous conditions. An alkane disulfonylchloride, such as methanedisulfonyl chloride, is dissolved in a suitable solvent, such as acetonitrile, and to this solution is added a silver salt, such as silver carbonate, in a molar ratio of slightly more than two moles of silver per mole of the disulfonyl chloride. The mixture is kept below 40°C during the initial exothermic reaction and is then stirred at room temperature for 24 hours.

-6-

The silver chloride powder which forms is removed by filtration. The reaction method, which is described in Example I below, yields approximately 88.5% of the theoretical yield of silver methanedisulfonate.

- 5 In the second step of the synthesis, the freshly prepared silver alkanedisulfonate is allowed to react with a dihalide of the form:




- where $n=1-4$ and X is either bromide or iodide. By way of illustration, silver methanedisulfonate dissolved in a suitable solvent, such as acetonitrile, is added to the dihalide, in approximately a 1 to 1 molar ratio, and the mixture is allowed to stand for up to several weeks at room temperature or is heated under reflux for up to several days in the absence of light. The precipitated silver salt is filtered and the filtrate is evaporated under reduced pressure, leaving a typically light brown, oil-like residue containing the desired product. The residue is dissolved in a suitable solvent, such as methylene chloride, and may be treated with a purifying agents such as decolorizing charcoal added to the solvent. To crystallize the product, a second solvent, such as cyclohexane, is added until a cloudy supernatant forms. Recrystallization in a solvent system such as cyclohexane:methylene chloride 2:1 may be carried out to achieve a desired purity. The identity of the product can be confirmed by characteristic infrared (IR) features, such as CH_2 and SO_2 stretching frequencies, and by proton nuclear magnetic resonance (NMR) features, such as the resonance positions of the CH_2-SO_2 proton, the end- CH_2-O proton and the middle CH_2 proton. Comparing experimental product elemental analysis with theoretical values provides further product-identity confirmation.
- 10
15
20
25
30

-7-


Example II describes the preparation of tetramethylene methanedisulfonate ($m=0$, $n=4$, $R=H$), also named 1,5,2,4-dioxadithiocane-2,2,4,4-tetroxide, from 1-4 dibromobutane and silver methanedisulfonate. The procedure yielded, upon recrystallization, small white needles whose final weight represented an approximately 3.79% total yield. In Example III, the preparation of trimethylene methanedisulfonate ($m=0$, $n=3$, $R=H$), also named 1,5,2,4-dioxadithiocane-2,2,4,4-tetroxide, from silver methanedisulfonate and 1,3-dibromopropane is detailed. An approximate 11% yield of small white crystals identified as trimethylene methanedisulfonate was obtained. Example IV describes the synthesis of ethylene methanedisulfonate. Alternative procedures described in this example gave yields, upon recrystallization in a cyclohexane-methylene chloride mixture, of 2.18% and 2.78%. The method of synthesis of methylene methanedisulfonate ($m=0$, $n=1$, $R=H$), also named 1,5,2,4-dioxadithiane-2,2,4,4-tetroxide, is described in Example V, and includes allowing silver methanedisulfonate to react in acetonitrile with an approximately equal molar amount of diiodomethane. A total product yield of about 2.22% was obtained.

A second general method for the synthesis of the novel cyclic disulfonate esters is particularly suitable for compounds whose structures correspond to those in which $m=0$ and $n=2-5$, and $R=H$ or CH_3 . The method generally includes adding a diol of the form:



where $n=2-5$, to a solvent such as tetrahydrofuran or the dimethyl ether of ethylene glycol (glyme), and adding to this solution, in the same solvent, an approximately equal molar amount of an alkanedisulfonyl chloride of the form:

-8-



where R=H or CH₃. The mixture is cooled to at least about -20°C and an aliphatic or aromatic tertiary amine is added dropwise to the mixture. Preferred tertiary amines include triethylamine and collidine, a tertiary aromatic amine. The reaction mixture is allowed to warm to 0°C or slightly higher and the hydrochloride salt which forms is removed by filtration. The filtrate is evaporated under reduced pressure, and the residue, which generally includes a light yellow oil, is dissolved in a suitable solvent, such as methylene chloride. A light crystalline powder, representing the desired recrystallized product, is obtained by crystallization in a suitable solvent system such as methylene chloride:cyclohexane. The identity of the product may be confirmed by characteristic IR and NMR features, such as those mentioned above, and by elemental analysis.

Example VI below describes the synthesis of pentamethylene methanedisulfonate (m=0, n=5, R=H), also named 1,5,2,4-dioxadithiocane-,2,4,4-tetroxide, according to the just-described method. A solution of 1-5-pentanediol in glyme was mixed with methanedisulfonyl chloride in the same solvent, and to this mixture was added triethylamine dropwise under anhydrous conditions. After removing the amine hydrochloride residue and evaporating the solvent, the oily residue was redissolved in methylene chloride, washed with 3 different aqueous wash solutions, and crystallized from a methylene chloride:cyclohexane solvent system. The procedure gave an approximately 6.75% yield of pure product. Examples VII and VIII

-9-

describe similar reaction procedures for the synthesis of ethylene methanedisulfonate ($m=0$, $n=2$, $R=H$) from ethylene glycol and methanedisulfonyl chloride in tetrahydrofuran, with the dropwise addition of collidine. A 25% yield of recrystallized product was obtained. Examples IX and X describe similar reaction methods for producing trimethylene and tetramethylene methanedisulfonate, respectively.

Examples XI-XIV describe the synthesis of 1,1-ethanedisulfonates ($m=0$, $R=CH_3$) in which $n=5$ (Example XI), $n=4$ (Example XII), $n=3$ (Example XIII) and $n=2$ (Example IX). It is noted that the cyclic disulfonate compound in which $n=1$ cannot be synthesized by the present synthetic method. In Example XI, a 2% product yield of pentamethylene 1,1-ethanedisulfonate, was formed. In Example XII, a 0.2% product yield of purified tetramethylene 1,1-ethanedisulfonate, was obtained. The method of Example XIII gave an approximately 36% product yield of the trimethylene 1,1-ethanedisulfonate, and Example XIV produced a 25% product yield of purified ethylene 1,1-ethanedisulfonate.


It will be appreciated from the examples that the general synthetic methods described can be modified readily, particularly with respect to the alkanedisulfonyl chloride starting material, to produce compounds having various indicated R groups and m values.

II. The Cyclic Disulfonate Ester Alkylation Reaction

The cyclic disulfonic ester compound of the present invention has a chemically reactive center at each of the CH_2-O group carbons, which is capable of reacting with a nucleophile-containing biomolecule. The initial alkylation reaction between a first nucleophile, designated $-N_1$, and the cyclic disulfonic ester

-10-

results in the formation of a linear intermediate of the form:



having a negatively charged SO_3^- end-group. It can


- 5 be appreciated that the linearized alkylating intermediate has markedly different solubility and charge characteristics from those of the cyclic compound. It is expected that these charge and solubility characteristics will affect the configuration
- 10 which the compound adopts with respect to the alkylated biomolecule. In particular, the charged end group may interact with positively charged histones associated with duplex DNA. Preliminary experiments conducted in support of the present invention indicate that the
- 15 cyclic ethylene disulfonic ester ($n=2$) is active in cross-linking DNA with DNA-associated proteins, in both human embryonic lung fibroblasts, cell line IMR-90, and its SV-40-transformed counterpart, cell line VA-13 (which has lost the ability to repair small alkyl
- 20 lesions at the O6-position of guanine). Interestingly, little or no DNA/DNA crosslinking was observed in cells treated with the $n=2$ compound, although high levels of both frank strand breaks and alkali-labile lesions (pH 12.6) were observed in both cell types treated with the
- 25 $n=2$ compound. The high levels of detected strand breaks and the lower toxicity seen in the IMR-90 cell line, which is capable of removing small alkyl lesions at the O6 position of guanine, suggest that the strand breaks observed may not be drug induced, but induced by the
- 30 enzymatic repair activity.

Following the initial alkylation event, the linearized charged complex can participate in a second nucleophilic reaction, with a second nucleophile N_2 .

-11-

forming a cross-linked- $N_1-(CH_2)_n-N_2$ complex, and releasing a second charged sulfonic acid.

The present invention more generally contemplates disulfonic esters which are characterized by a sulfonic acid end-group after an initial alkylation reaction. A class of linear disulfonic esters having this property have the general structural formula:



reference to this structure, it can be appreciated that initial nucleophilic attack by a nucleophile N_1 at an $O-CH_2$ carbon, produces an N_1 -alkylating agent complex which is identical to the complex formed after the initial nucleophilic reaction involving the corresponding cyclic disulfonic ester.

Example XV below outlines a procedure for the synthesis of 1,2-bis(oxysulfonylmethanesulfonic acid)ethane ($m=0$, $R=H$, $n=2$). In the method, methanedisulfonyl chloride is allowed to react with water in the presence of diethyl ether to produce the corresponding chlorosulfonylmethanesulfonic acid. The sulfonic acid group in this chemical intermediate is protected by reaction with trimethylsilyl chloride or *t*-butyldimethylsilyl chloride, according to known procedures. The compound is then allowed to react with ethylene glycol in a suitable solvent, such as glyme, with the addition of an aromatic or aliphatic tertiary amine such as triethylamine dropwise at $-20^\circ C$. The product is treated with H_2O and bicarbonate salt to hydrolyze the silyl esters in the compound, forming the desired salt of the product.

-12-

III. Anti-cancer Activity of Cyclic Methanedisulfonate Esters

The effectiveness of cyclic methanedisulfonate esters against various types of mammalian cancers was studied. Individual strains of mice identified as having one of the following types of cancer were employed in the study: lymphocytic leukemia, lymphoid leukemia, melanocarcinoma, human breast xenograft and ovarian carcinoma. For each type of cancer, a group of animals all of about the same size and weight were treated with one of a number of increasing dose levels of the test drug, to identify optimal dosage levels, as evidenced by either maximum survival period or inhibition of tumor growth.

In each test, animals were divided into two equal-number groups: a control group which received the drug carrier alone; and the treated group which received the drug, at optimal dose levels in the drug carrier. In the studies involving lymphocytic leukemia, lymphoid leukemia, melanocarcinoma, and ovarian carcinoma, drug effectiveness was measured by the ratio of median number of days the treated animal survived (T) to the median number of days the control animal survived (C), designated the T/C ratio. Drug effectiveness against human breast xenograft was measured by the ratio of tumor size for treated (T) to tumor size for control (C) animals.

The treatment protocol and results obtained for ethylene methanesulfonate drug treatment are described in Example XVI. The data show that ethylene methanesulfonate substantially prolongs survival time or inhibits tumor growth for all types of cancers which are reported in the example.

-13-

Two additional groups of mice having lymphocytic leukemia were treated with either trimethylene methanedisulfonate (n=3) or tetramethylene methanedisulfonate (n=4) for purposes of comparing the therapeutic effectiveness of cyclic disulfonic ester compounds having n=2-4 cross-linking chain lengths. The test conditions and protocol are substantially like those employed in the Example XVI tests, and are described in Examples XVII and XVIII, respectively, for the n=3 and n=4 compounds. Both the trimethylene and tetramethylene methanedisulfonate compounds showed significant anti-leukemic activity, as measured by their T/C ratios, but both were substantially less effective than the cyclic ethylene methanedisulfonate ester in prolonging survival in leukemic animals.

From the foregoing, it can be appreciated how various objects of the invention are met. The cyclic disulfonic esters described herein provide a new class of cross-linking agents whose structure and reaction are quite different from uncharged, linear disulfonic esters. One of the novel compounds of the invention has been shown to be useful in the treatment of a variety of cancers including leukemias, ovarian carcinoma, melanocarcinoma and breast xenograft.

The compounds of the invention are readily synthesized by one or both of the methods detailed herein, and for several of the compounds, product yields greater than about 25% may be achieved.

The following examples illustrate various methods of synthesis and treatment protocols associated but are not intended to limit the scope of the invention.

-14-

Example IPreparation of Anhydrous Silver Methanedisulfonate

Completely anhydrous and dark conditions were employed throughout the preparation. All glassware was
5 baked in an oven at 110°C for at least one-half hour. Methanedisulfonyl chloride was synthesized according to known methods; see, e.g., Schroeter, G., Ann Chem (1919) 161-257. Redistilled methanedisulfonyl chloride (2.00 g, 0.009 mole), was transferred in 15 ml of acetonitrile
10 obtained from Burdick and Jackson Laboratories (Muskegon, MI) to an equalizing dropping funnel. The acetonitrile was dried by distillation over P_2O_5 . Analytical grade silver carbonate obtained from J.T. Baker Chemical Co. (Phillipsburg, NJ) (99.8%) was
15 weighed (5.22 g, 0.019 mole) and placed into a three-neck flask fitted with an equalizing funnel, a reflux condenser with a drying tube, and a thermometer. A stir bar was added and the disulfonyl chloride solution was allowed to drop in slowly. The mixture
20 became warm and a gas was evolved. The temperature was kept below 40°C in an ice-water bath. The stir bar was started as soon as possible and the mixture was stirred at room temperature for approximately 24 hours. The reaction mixture was filtered, yielding a light purple
25 powder containing silver chloride and unreacted silver carbonate. The weight of the dried powder was 2.99 g, 0.29 g over the theoretical weight of silver chloride assuming complete reaction of the silver carbonate. Based on these numbers, the yield of silver
30 methanedisulfonate in the filtrate was calculated to be about 88.5%.

-15-

Example IIPreparation of Tetramethylene Methanedisulfonate

Purified 1,4-dibromobutane obtained from Aldrich Chemical Co. (Milwaukee, WI) (2.03 g, 0.009 mole) was added to a flask containing 100 ml of freshly prepared solution of silver methanedisulfonate in acetonitrile from Example I. The flask was stoppered and placed in the dark at room temperature for a period of 8 weeks, during which a yellow-green precipitate formed and settled to the bottom of the flask. The suspension was filtered, and the filtrate was washed with dry acetonitrile, leaving silver bromide in suspension. The suspension was filtered and the filtrate dried as in Example I. The dried weight of the filtrate was 2.34 grams, or 67.7% of the theoretical expected weight of silver bromide, based on complete reaction of dibromobutane with the silver methanedisulfonate.

The original filtrate was evaporated under reduced pressure, leaving a light brown oil. Washing the oil with methylene chloride turned the oil into a brown gum and a cloudy supernatant. The supernatant was decanted and treated with decolorizing charcoal. Removal of the charcoal by filtration left a colorless, clear solution. The solvent was removed under reduced pressure, yielding small white cubic crystals. The crystals were recrystallized from a 2:1 cyclohexane-methylene chloride mixture. Small white needles were recovered, dried, and weighted. The weight was 0.082 g, representing a 3.79% yield. The product had a melting point at 143-144°C. NMR and IR spectral analysis of the sample showed the spectral characteristic expected for tetramethyl methanedisulfonate. Elemental analysis of the product

-16-

calculated for $C_5H_{10}O_6S_2$ is: C, 26.08; H, 4.38; S, 27.85. The experimental values were C, 26.08, H, 4.77; and S, 27.66.

Example III

5 Preparation of Trimethylene Methanedisulfonate

Purified 1,3-dibromopropane obtained from Aldrich Chemical Co. (4.76 g, 0.024 mole) was added to a freshly prepared silver methanedisulfonate solution in 100 ml of dry acetonitrile from Example I. The mixture
10 was heated under reflux at 82° for 3 days, after which a yellow-green powder formed. The powder was filtered, washed with dry acetonitrile, filtered, dried and weighted. The dry weight of 5.92 grams represented 65.5% of the expected weight of silver bromide, based on
15 complete reaction of the dibromopropane with silver methanedisulfonate. The solvent from the reflux reaction was removed under reduced pressure, and the remaining oil was treated by the procedure described for the purification of tetramethylene methanedisulfonate in
20 Example II. The small white crystals obtained weighed 0.563 grams, representing an 11% yield, and showed melting points between 156 and 157.5°C and 185.5 and 186.5°C. NMR and IR spectra of the twice recrystallized compound showed the characteristic features of
25 trimethylene methane disulfonate. The calculated elemental analysis for $C_4H_8O_6S_2$ is C, 22.22; H, 3.72; and S, 29.66. The experimental values were: C, 22.31; H, 3.69; and S, 28.91.

Example IV

30 Preparation of Ethylene Methanedisulfonate

Purified 1,2-dibromoethane obtained from Aldrich Chemical Co. (4.42 g, 0.024 mole) was added to a

-17-

freshly prepared silver methanedisulfonate solution in approximately 100 ml of acetonitrile, prepared in accordance with Example I. After 4 days of heating under reflux at 82°, the reaction mixture was cooled and
5 filtered. The yellow-green powder thus obtained was washed with acetonitrile, dried, and weighed. The 4.01 gram weight of the dried powder represented 44.5% of the expected weight of silver bromide, based on complete reaction. The filtrate from the reflux reaction was
10 removed under reduced pressure, leaving a light brown viscous oil. The oil was treated with methylene chloride, as in Example II, forming a cloudy white supernatant and an opaque brown gum. The supernatant was decanted and treated with decolorizing charcoal and
15 diatomaceous earth. The solution, after filtering, was clear and colorless. The solvent was removed under reduced pressure leaving small white crystals. These were recrystallized from a cyclohexane-methylene chloride mixture and vacuum dried. The dried weight was
20 0.113 g, representing a 2.18% theoretical yield, and the melting point was about 170°C. IR and NMR spectra of the recrystallized product showed the characteristic features of ethylene methanedisulfonate. Atomic analysis was in conformity with the values calculated
25 for $C_3H_6O_6S_2$.

The same procedure described above was repeated, using 5.09 g, 0.028 mole of purified 1,2-dibromoethane and a 100 ml solution of silver methanedisulfonate. The reaction was heated under
30 reflux at 82°C for one day. The yellow-green powder weighed 3.55 g, 0.75 g less than the weight of the expected AgBr. Small white needles having a total weight of 0.162 g, representing a 2.78% yield, were obtained.

-18-

Example VPreparation of Methylene Methanedisulfonate

A flask containing approximately 100 ml of silver methanedisulfonate solution was equipped with a
5 reflux condenser and a drying tube. Purified diiodomethane obtained from Aldrich Chemical Co. (5.09 g, 0.019 mole) was added and the solution was heated under reflux for 2 days. A light yellow powder which formed was filtered, washed, and dried, as in Example
10 II. The dried precipitate weighed 5.79 g, representing 72.0% of the weight of the expected AgI. The filtrate was treated as described in Example II to obtain small white needles having a total weight of 0.081 grams, representing a yield of 2.22%, and having a melting
15 point of between 146°C and 146.5°C. IR and NMR spectral analysis of the white needles, after further recrystallization, showed the features characteristic of methylene methane disulfonate. Elemental analysis calculated for $C_2H_4O_6S_2$ was: C, 12.76; H, 2.14;
20 and S, 34.09 for $C_2H_4O_6S_2$. The measured values were: C, 12.91; H, 2.14; and S, 34.16.

Example VIPreparation of Pentamethylene Methanedisulfonate

The present example and following Examples
25 VII-XII detail the synthesis of cyclic alkane disulfonic esters by the reaction of an alkane disulfonyl chloride with diols of the type: $HO-(CH_2)_n-OH$ where n=2, 3, 4 or 5.

Dimethyl ether of ethylene glycol (glyme)
30 obtained from Burdick and Jackson Laboratories was purified by distillation over sodium and benzophenone. A solution of 1,5-pentanediol obtained from Aldrich Chemical Co. (12.5 g, 0.12 mole) in 350 ml of purified

-19-

glyme was stirred in a 3-neck 1 liter round bottom flask equipped with a stirrer and a thermometer. The reaction flask was maintained at a temperature of -20°C by a downanol-dry ice bath. Methanedisulfonyl chloride, prepared according to the method described by Fild, M. and Rieck, H. P., Chem Zeitung (1976) 109(9):391, (25.6 g, 0.12 mole), dissolved in 25 ml of glyme, was slowly added through a 60 ml dropping funnel. A solution of triethylamine obtained from Eastman Organic Chemicals (Rochester, NY) (24.3 g, 0.24 mole) in 125 ml of glyme was added dropwise to the vessel over a one hour period. Care was taken to avoid contact with water by covering the dropping funnels with drying tubes filled with CaCl_2 . Once all additions were complete, the reaction mixture was allowed to return to room temperature and stirred for two hours.

The reaction mixture was vacuum filtered to remove the solid triethylamine hydrochloride. The solid amine hydrochloride residue, which was washed with glyme and then allowed to dry, weighed 37.0 g, representing a 104% calculated theoretical yield. The filtrate was roto-evaporated below 37°C to remove the glyme. The residue was redissolved in 100 ml of methylene chloride and washed with the following series of cold, aqueous washes: a) three times with 30 ml of 5% sodium bicarbonate;; b) one time with 30 ml of distilled water; and c) three times with 30 ml of 5% hydrochloric acid. These wash solutions were cooled to 4°C to minimize product hydrolysis. The final organic layer was dried over MgSO_4 and the methylene chloride was removed by roto-evaporation. The crude product was redissolved in a minimal amount of methylene chloride. Cyclohexane was added until the mixture was placed in a refrigerator for one month and additional cyclohexane was added to the

-20-

mixture periodically as the mixture cleared, to promote product crystallization. The white powder which formed was filtered and dried. A total amount of 0.22 grams, representing a 6.75% yield of the crystallized product, was obtained. The product decomposed at between 102°C and 105°C and was identified by characteristic CH_2 and SO_2 IR characteristics and $\text{CH}_2-(\text{SO}_2)_2$, CH_2-O and $-\text{CH}_2-$ proton NMR characteristics.

Example VII

10 Preparation of Ethylene Methanedisulfonate - Method 2

Tetrahydrofuran, obtained from Burdick and Jackson Laboratories was freshly distilled from sodium benzophenone according to standard procedure. A solution of ethylene glycol obtained from Aldrich Chemical Co. (1.24 gram) in 200 ml tetrahydrofuran was added to a 500 ml 3-neck flask filled with a 50 ml pressure-equalizing dropping funnel connected to a drying tube, a mechanical stirrer and a low temperature thermometer. The solution was cooled to -20°C and 4.26 gram (0.02 mole) of methanedisulfonyl chloride in 50 ml tetrahydrofuran was added from the dropping funnel over a period of 15 minutes. Collidine, obtained from Eastman Organic Chemicals (4.85 g, 0.04 mole) in 120 ml tetrahydrofuran was then added slowly to the flask over a period of about 1 hour. The reaction mixture was allowed to warm to 10°C and the collidine hydrochloride which formed was removed by filtration. The filtrate was concentrated on the rotary evaporator at 20 mm pressure. The residue was placed under a high vacuum (1-2 mm) for about 15 minutes, then 50 ml of cold 5% HCl was added and the mixture was placed in the refrigerator overnight. Filtration, followed by vacuum drying, produced 1.02 g, representing a 25% yield of the

-21-

ethylene glycol ester of methanedisulfonic acid, m.p. 165-169°C. The identity of the product was confirmed by IR and proton NMR spectra.

Example VIII

5 Preparation of Ethylene Methanedisulfonate - Method 3

In a modification of the method described in Example VII, glyme was used in place of tetrahydrofuran and triethylamine, in place of the collidine. The triethylamine hydrochloride was not filtered and the
10 final reaction solution was evaporated under vacuum, and the residue was taken up in ice cold water and filtered to give 4.67 g (57% yield) of ethylene methanedisulfonate from 0.04 mole of methanedisulfonyl chloride. This product was further purified by vacuum
15 sublimation at 0.5 to 1.0 mm of Hg in a bath heated to 95°C-102°C. Sublimation removed one of the impurities noted in the NMR spectrum. The sublimed material was submitted for biological testing.

Example IX

20 Preparation of Trimethylene Methanedisulfonate

Method 2

The procedure described in Example VIII, substituting 1,3-propanediol for ethylene glycol, was followed with glyme as the solvent and triethylamine as
25 the base. The residue, after evaporation of the glyme, was taken up in methylene chloride and washed successively with sodium bicarbonate, water, and 5% hydrochloric acid. After drying the methylene chloride over anhydrous magnesium sulfate, cyclohexane was added
30 to induce crystallization. From 25.6 g (0.12 mole) of 1,3-propanediol and 24.3 g (0.24 mole) of triethylamine, 2.6 g (10% yield) of trimethylene methanedisulfonate was

-22-

obtained. The compound was identified by m.p. at 139°C-142°C (dec), and by IR and NMR spectra.

Example X

Preparation of Tetramethylene Methanedisulfonate

5

Method 2

The same procedure as described in Example VIII, substituting 1,4-butanediol for ethylene glycol, was used, and from the same molar quantities of reagents there was obtained a 7% yield of the ester, identified
10 by m.p. 135°C-136°C (dec), and by IR and NMR spectra.

Example XI

Preparation of Pentamethylene 1,1-Ethanedisulfonate

1,5-Pentanediol (4.17 g, 0.04 mole) was dissolved in 350 ml of glyme in a 1 liter round bottom
15 flask and the solution brought to -20°C.
1,1-ethanedisulfonyl chloride, synthesized in the same manner as the methanedisulfonyl chloride, (Example I) was dissolved in 25 ml of glyme and this solution added dropwise to the solution in the flask. Triethylamine
20 (8.08 g, 0.08 mole) was dissolved in 125 ml of glyme and this solution was added to the pentanediol/
ethanedisulfonyl chloride solution over a 1 hour period. After the additions were completed, the mixture was brought to 25°C over a 45 minute period in a water
25 bath. The mixture was roto-evaporated under reduced pressure, at a temperature below 35°C. The residue was washed three times with 20 ml of 5% sodium bicarbonate the resulting emulsion being separated by centrifugation. Water was decanted from the final oil
30 wash, and methylene chloride was added. This solvent apparently dissolved all or most of the impurities, leaving the product suspended in the solution. The

-23-

product was obtained by vacuum filtering the solution through Whatman #5 qualitative filter papers.

The dried product weighed 0.22 grams, representing about a 2% product yield. The product was identified by characteristic IR and proton NMR spectra. Product decomposition occurred between 141°C and 142°C. The limited solubility of the compound was confirmed by dissolving 0.03 grams of the dried product in 1 ml acetonitrile and in 1 ml of methylene chloride. In each case, evaporation of the supernatant decanted from the undissolved solid showed that less than 0.01 grams of the pentamethylene ethanedisulfonate product had dissolved in each solvent.

Example XII

Preparation of Tetramethylene 1,1-Ethanedisulfonate

1,4-Butanediol, obtained from Aldrich Chemical Co. (3.6 g, 0.04 mole) was dissolved in 75 ml of glyme in a 1 liter round bottom flask. A solution of 1,1-ethanedisulfonyl chloride (9.1 g, 0.04 mole) dissolved in 25 ml of glyme was added to the flask through a dropping funnel. The reaction mixture was kept below -20°C with a dowlanol-dry ice bath. Triethylamine (8.08 g, 0.08 mole) dissolved in 100 ml of glyme was added to the mixture through a 125 ml dropping funnel over a period of 1 hour. Care was taken to maintain anhydrous conditions by covering the dropping funnels with drying tubes containing CaCl_2 . The reaction mixture was brought to 25°C in a cold water bath. The glyme was removed by foto-evaporation, at a temperature below 37°C. The oily yellow residue that remained after removal of the glyme was washed once with 100 ml of 5% sodium bicarbonate and once with 50 ml of cold distilled water, the resulting emulsion being

-24-

centrifuged immediately to separate the product, and aqueous material decanted. The remaining precipitate was dried under vacuum. The white, powdery solid which remained weighed 0.90 g. representing a 9.2% yield.

- 5 Product identification was confirmed by characteristic IR and proton NMR spectral features. The product decomposed between 115 and 138°C. The product was soluble to less than about 0.01 gram in 1 ml of either methylene chloride or acetonitrile.

10

Example XIII

Preparation of Trimethylene 1,1-Ethanedisulfonate

- 1,3-Propanediol obtained from Aldrich Chemical Co. (6.1 g, 0.08 mole) was dissolved in 350 ml of distilled glyme in a 3-neck, 1 liter round bottom flask equipped with a stirrer and a thermometer. The solution was maintained at -20°C in a dowlol-dry ice bath placed underneath the flask. A solution of 1,1-ethanedisulfonyl chloride (18.2 g, 0.08 moles) dissolved in 25 ml of glyme was slowly added through a 60 ml dropping funnel. Following this addition, a mixture of triethylamine (16.2 g, 0.16 mole) dissolved in 125 ml of glyme was added dropwise to the vessel over a 1 hour period. Care was taken to avoid contact with water by covering the dropping funnels with drying tubes filled with CaCl_2 . Once all additions were completed, the reaction mixture was brought to room temperature and stirred for 3 hours.

- The reaction mixture was vacuum filtered to remove solid triethylamine hydrochloride. The filtrate was roto-evaporated at a temperature below 37°C to remove glyme. The crude product, having a weight of 7.95 g, was redissolved in a minimal amount of methylene chloride, and cyclohexane was added until the mixture

-25-

- turned cloudy. The initial crystals which formed were removed from solution by vacuum filtration, and additional cyclohexane was added to produce a second crop of crystals, which was also removed by filtration.
- 5 The two crops of crystals were washed with cold distilled water to remove the surface film of oil. The final weight of solid obtained represented a 36% product yield. The sample decomposed between 151°C and 155°C, when added to an already heated melting-point
- 10 apparatus. Product identity was confirmed by IR spectral features related to CH_3CH and SO_2 , and by proton NMR features related to CH , CH_2O , $-\text{CH}_2-$ and $-\text{CH}_3$.

Example XIV

15 Preparation of Ethylene 1,1-Ethanedisulfonate

- The reaction procedure described in Example XIII for the preparation of trimethylene 1,1-ethanedisulfonate was followed, substituting for the 1,3-propane diol used in Example XIII, ethylene glycol
- 20 (5.0 gram, 0.008 mole). The reaction mixture was stirred for 3 hours at room temperature, the solid amine hydrochloride residue removed, and the filtrate roto-evaporated to remove glyme. The crude product obtained was redissolved in a minimum amount of
- 25 methylene chloride, and subsequent addition of cyclohexane produced white crystals immediately. Several crops of crystals totaling 5.84 grams were obtained after further addition of cyclohexane and refrigeration. Further recrystallization of the
- 30 material resulted in a total of 4.37 grams of product, representing a 25.2% yield. The product melting point was between 92°C and 93°C. Product identification was confirmed by IR spectral features relating to CH_3CH

-26-

and SO_2 and proton NMR features relating to CH , CH_2 and CH_3 .

Example XV

Preparation of Sodium 1,2-bis (oxysulfonylmethane sulfonate) Ethane

5 Methanedisulfonyl chloride, 25.0 g (0.117 mole), was placed in a 500 ml round-bottom flask containing 200 ml of anhydrous ether. To this stirred solution was slowly added 2.1 g (0.117 mole) water while
10 the solution was cooled in an ice bath. After the addition of water, the ice bath was removed and the solution was stirred for four hours. The ether was removed by rotary evaporation, and 37 g (0.35 mole) of freshly distilled trimethylsilyl chloride obtained from
15 PCR Research Chemicals, Inc., (Gainesville, FL) was added slowly, using a bubbler to monitor gas evolution. After the addition of trimethylsilyl chloride, the solution was heated to reflux for several hours until gas evolution ceased. Excess trimethylsilyl chloride
20 was removed by evaporation and the residue was fractionated, giving 24 g (77%) of trimethylsilyl chlorosulfonylmethanesulfonate, bp 102°C - 104°C at 0.2 mm pressure, or 110°C - 111°C at 0.4 mm pressure. Product identification was confirmed by titration and by NMR
25 spectra.

To a solution of 5.52 g (0.0207 mole) of trimethylsilyl chlorosulfonylmethanesulfonate in 25 ml of glyme (freshly distilled from sodium and benzophenone and cooled to -20°C) was added dropwise a solution of
30 0.62 g (0.01 mole) of ethylene glycol and 1.75 g (0.02 mole) of triethylamine in 25 ml of glyme. The solution was then allowed to warm to room temperature, filtered, and the glyme removed by evaporation. Two equivalents

-27-

of sodium bicarbonate in water were added and, after the gas evolution had ceased, the aqueous solution was washed with methylene chloride and then evaporated to leave a white foamy residue containing the sodium salt of 1,2-bis (oxysulfonylmethanesulfonic acid) ethane.

Example XVI

Anti-cancer Activity of Ethylene Methanedisulfonate

Individual strains of mice identified as having the following types of cancer were employed in the present study: lymphocytic leukemia (PS), lymphoid leukemia (LE), melanocarcinoma (B1), human xenograft (MB) and ovarian carcinoma (M5). The left-hand column of Table I below identifies the 6 test systems which were studied, including 2 different lymphoid leukemia groups, identified as LE31 and LE37. For each test system, 6 to 10 animals received a daily dose of ethylene methanedisulfonate, at the dosage indicated in the Dose Range column in the table. The injection route was either intraperitoneal (IP), intracerebral (IC), or subcutaneous (SC), as indicated in the third column from the left in the table. The dose range was that found to be most therapeutically effective against the specified cancer, using the injection route indicated. An equal number of mice received a daily administration of the drug delivery vehicle only (controls).

The control and drug-treated animals were kept on this regimen until all the animals had died, except that in the few cases where the survival time was more than three times that of the control, the test animals were designated as cured. The T/C ratio, shown at the right-hand column in Table I, is calculated as the percentage ratio of the median number of days of survival of treated animals (T) divided by the median

-28-

number of days of control animals (C). Thus, for the PS 31 test system, the T/C value of 270 indicates that the median number of days of survival of treated animals was 270% or 2.7 times the median number of days of survival of untreated animals. In the case of the human breast xenograft test system (MBG5), the T/C ratio provides a measure of the tumor size of treated animals versus that of untreated. The value of 7 means that the tumor of treated animals averaged about 7% of the growth of that of untreated animals.

TABLE I

		Injection	
<u>Test System</u>	<u>Dose Range</u>	<u>Route</u>	<u>T/C Med.</u>
3 PS 31	25-50 mg/kg	IP	270
15 3 LE 31	25-50 mg/kg	IP	271
06 LE 37	6.25-25.0 mg/kg	IC	183
3 B 131	12.5-25.0 mg/kg	IP	166
3 MB G5	50-300 mg/kg	SC	(7)
3 M5 31 (M)	12.5-50 mg/kg	IP	217
20 3 M5 31 (F)	25-50 mg/kg	IP	267

The data in Table I show that ethylene methanedisulfonate was effective, at various dose ranges, in treating all five types of cancer studied, and that the drug delivery could be achieved by a variety of injection routes.

Example XVII

Anti-Leukemic Activity of
Trimethylene Methanedisulfonate

A test system corresponding to PS 31 in Table I was carried out to test the effectiveness of trimethylene methanedisulfonate against lymphocytic

-29-

leukemia. The test protocol was identical to that used in test system PS31 in Example XVI, with the exception that the optimal dose range of between 6.5 and 12.5 mg drug per kilogram body weight was used. The T/C ratio, calculated on the basis of the median number of days survival of treated and untreated animals, was 160, indicating that the drug is effective in the treatment of lymphocytic leukemia, but substantially less so than ethylene methanedisulfonate.

10

Example XVIIIAnti-Leukemic Activity of
Tetramethylene Methanedisulfonate


The effectiveness of the tetramethylene methanedisulfonate compound in treating lymphocytic leukemia in a test system like test system PS 31 of Example XVI was examined. The test employed the same general protocol, including the same number of animals and injection route described in Example XVI for test system PS 31, except that the optimal drug dosage for the tetramethylene methanedisulfonate compound of 12.5 to 25 mg per kilogram of body weight was administered. The T/C ratio, calculated on the basis of number of median number days survival of treated and untreated animals, was 188, similar to the results obtained with trimethyl methanedisulfonate.

While the invention has been described with respect to preferred embodiments and specific examples, it will be appreciated that various changes and modifications may be made without departing from the spirit of the invention.

-30-

WHAT IS CLAIMED IS:

1. A bifunctional alkylating compound comprising a cyclic disulfonic ester of the form



5 where $m=0$ or 1 , $n=1-5$, and $\text{R}=\text{H}$, CH_3 , CH_3CH_2 or Cl .


2. The compound of claim 1, wherein $m=0$, and $\text{R}=\text{H}$, CH_3 or Cl .

3. The compound of claim 2, wherein $m=0$ and
10 $\text{R}=\text{H}$.

4. The compound of claim 3, wherein $n=2$.

5. The compound of claim 1, wherein $n=2$.

6. The compound of claim 3, formed by the steps of reacting an alkanedisulfonyl chloride of the
15 form




where $\text{R}=\text{H}$ or CH_3 , with silver carbonate to form the corresponding silver alkanedisulfonate, and allowing the disulfonate to react with a dehaloalkane of the form


20 $\text{X}-(\text{CH}_2)_n-\text{X}$
where $\text{X}=\text{Br}$ or I , and $n=1-5$.

-31-

7. The compound of claim 1, formed by the steps of allowing an alkane disulfonyl chloride of the form




where R=H or CH₃, to react with an alkane diol of the form



where n=2-5, in the presence of tetrahydrofuran or glyme and an aliphatic or aromatic tertiary amine.


8. The compound of claim 7, wherein the tertiary amine is added dropwise to the other reactants at a reaction temperature below about -20°C.

9. A bifunctional alkylating compound capable of reacting with a first nucleophile -N₁ to produce a nucleophile-reactive intermediate of the form



10. The compound of claim 9, wherein n=2 and R=H.


11. The compound of claim 9, which includes a cyclic disulfonic ester of the form




where n=1-5.

-32-

12. The compound of claim 9, which includes a linear disulfonic acid of the form



13. An anti-cancer compound comprising a cyclic disulfonic ester of the form




where $n=2-4$.

14. The compound of claim 13, wherein $n=2$.

15. The compound of claim 14, for use in treating mammalian lymphocytic leukemia, lymphoid leukemia, melanocarcinoma, human breast xenograft and ovarian carcinoma.

16. A method of treating a mammalian cancer comprising administering a therapeutically effective amount of a cyclic disulfonic ester compound of the form



where $n=2-4$.

17. The method of claim 16, wherein $n=2$.

18. The method of claim 17, wherein the cancer includes lymphocytic leukemia or lymphoid leukemia, and said administering includes administering the compound

-33-

intraperitoneally, at a dose of between about 25 and 50 milligrams per kilogram of body weight.


19. The method of claim 17, wherein the cancer includes a lymphoid leukemia, and said administering
5 includes administering the compound intracranially at a dose of between about 6.25 and 25 milligrams per kilogram of body weight.

20. The method of claim 17, wherein the tumor
10 includes a melanocarcinoma, and said administering includes administering the compound intraperitoneally at a dose of between about 12.5 and 25 milligrams per kilogram of body weight.

21. The method of claim 17, wherein the cancer
15 includes a human breast xenograft and said administering includes administering the compound subcutaneously at a dose of between about 50 and 300 milligrams per kilogram of body weight.

22. The method of claim 19, wherein the cancer
20 includes an ovarian carcinoma, and said administering includes administering the compound intraperitoneally at a dose of between about 15 and 50 milligrams per kilogram of body weight.

23. A compound of the form



25 where $\text{R}_1 = \text{H}$, CH_3 or Cl , and $\text{R}_2 = \text{CH}_3$ or $\text{C}(\text{CH}_3)_3$.

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/US85/00057

I. CLASSIFICATION OF SUBJECT MATTER (If several classification symbols apply, indicate all) ¹		
According to International Patent Classification (IPC) or to both National Classification and IPC ²		
A61K 31/385, 31/39, 31/255, C07D 327/00; C07F 7/08		
II. FIELDS SEARCHED		
Minimum Documentation Searched ³		
Classification System	Classification Symbols	
U. S.	260/456 A, 456 R 556/428 424/276, 277, 303 549/11, 19	
Documentation Searched other than Minimum Documentation to the extent that such Documents are included in the Fields Searched ⁴		
III. DOCUMENTS CONSIDERED TO BE RELEVANT ^{1*}		
Category ⁶	Citation of Document, ¹² with indication, where appropriate, of the relevant passages ¹⁷	Relevant to Claim No. ¹³
X	AT, B, 210/874 Published 25 August 1960	1-15
Y	AT, B, 210/874 Published 25 August 1960	1- 22
Y	GB, A, 700,677 Published 09 December 1953 Timmis	15-22
Y	DE, B, 1,124,032 Published 22 February 1962	9, 12
Y,E	US, A, 4,483,799 Published 20 November 1984, Kampfer et al.	1-15
A,P	US, A, 4,483,799 Published 20 November 1984 Kampfer et al	1-22
A	DE, B, 1,277,247 Published 12 September 1968	1-15
A	N, Chemical and Pharmaceutical Bulletin, issued 01 November 1964, Hayashi et al, Studies on Anti Tumor Substances, Syn- thesis of Bis-(Methane Sulphonylthio) Alkanes pp 1271-72	1-22
<p>* Special categories of cited documents: ¹⁴</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</p> <p>"Δ" document member of the same patent family</p>		
IV. CERTIFICATION		
Date of the Actual Completion of the International Search ⁵	Date of Mailing of this International Search Report ⁸	
10 April 1985	24 APR 1985	
International Searching Authority ⁷	Signature of Authorized Officer ¹⁰	
ISA/US	